These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33298896)

  • 1. Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer.
    Falcicchio M; Ward JA; Macip S; Doveston RG
    Cell Death Discov; 2020 Nov; 6(1):126. PubMed ID: 33298896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
    Garufi A; Pistritto G; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 family members in cancer diagnosis and treatment.
    Machado-Silva A; Perrier S; Bourdon JC
    Semin Cancer Biol; 2010 Feb; 20(1):57-62. PubMed ID: 20206267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
    Dickens MP; Fitzgerald R; Fischer PM
    Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
    Shangary S; Wang S
    Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
    van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
    J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53-Mediated Indirect Regulation on Cellular Metabolism: From the Mechanism of Pathogenesis to the Development of Cancer Therapeutics.
    Wang CY; Chao CH
    Front Oncol; 2022; 12():895112. PubMed ID: 35707366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting mutant p53 for cancer therapy: direct and indirect strategies.
    Hu J; Cao J; Topatana W; Juengpanich S; Li S; Zhang B; Shen J; Cai L; Cai X; Chen M
    J Hematol Oncol; 2021 Sep; 14(1):157. PubMed ID: 34583722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and its isoforms in cancer.
    Bourdon JC
    Br J Cancer; 2007 Aug; 97(3):277-82. PubMed ID: 17637683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
    Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
    Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway.
    Hrstka R; Bouchalova P; Michalova E; Matoulkova E; Muller P; Coates PJ; Vojtesek B
    Mol Oncol; 2016 May; 10(5):652-62. PubMed ID: 26733232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy.
    Yu Q
    Drug Resist Updat; 2006; 9(1-2):19-25. PubMed ID: 16600668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
    Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.
    Munisamy M; Mukherjee N; Thomas L; Pham AT; Shakeri A; Zhao Y; Kolesar J; Rao PPN; Rangnekar VM; Rao M
    Am J Cancer Res; 2021; 11(12):5762-5781. PubMed ID: 35018225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications.
    Tabakin-Fix Y; Azran I; Schavinky-Khrapunsky Y; Levy O; Aboud M
    Carcinogenesis; 2006 Apr; 27(4):673-81. PubMed ID: 16308315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Awakening guardian angels: drugging the p53 pathway.
    Brown CJ; Lain S; Verma CS; Fersht AR; Lane DP
    Nat Rev Cancer; 2009 Dec; 9(12):862-73. PubMed ID: 19935675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Oncogenic Mutant p53 for Cancer Therapy.
    Parrales A; Iwakuma T
    Front Oncol; 2015; 5():288. PubMed ID: 26732534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Butein inhibits cancer cell growth by rescuing the wild-type thermal stability of mutant p53.
    Song B; Wang J; Ren Y; Su Y; Geng X; Yang F; Wang H; Zhang J
    Biomed Pharmacother; 2023 Jul; 163():114773. PubMed ID: 37156116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.